Trial Profile

A Noninterventional Extension Study for Patients Treated in Study R5459-RT-1944 With REGN5459 or REGN5458 (BCMA x CD3 Bispecific Antibodies) Who Receive A Kidney Transplant

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 25 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Linvoseltamab (Primary) ; REGN 5459 (Primary)
Indications Renal transplant rejection
Focus Adverse reactions
Sponsors Regeneron Pharmaceuticals

Most Recent Events

11 Mar 2025 Planned number of patients changed from 12 to 20.
11 Mar 2025 Planned End Date changed from 21 May 2026 to 24 Dec 2027.
11 Mar 2025 Planned primary completion date changed from 21 May 2026 to 15 Jun 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com